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S U M M A R Y
Background: This descriptive, non-comparative, phase III study evaluated the safety and tolerability of
cell culture-derived (TIVc) and egg-derived (TIV) seasonal inﬂuenza vaccines in children at risk of
inﬂuenza-related complications.
Methods: Four hundred and thirty subjects were randomized 2:1 to TIVc or TIV. Subjects aged 3 to <9
years received one dose (if previously vaccinated, n = 89) or two doses (if not previously vaccinated,
n = 124) of the study vaccines; the 9 to <18-year-olds (n = 213) received one dose. Reactogenicity was
assessed for 7 days after vaccination; safety was monitored for 6 months.
Results: After any vaccination, the most frequently reported solicited local adverse event (AE) was
tenderness/pain (TIVc 44%, 66%, 53% and TIV 56%, 51%, 65% in the age groups 3 to <6 years, 6 to <9 years,
and 9 to <18 years, respectively) and the systemic AE was irritability (22% TIVc, 24% TIV) in 3 to <6-year-
olds and headache in 6 to <9-year-olds (20% TIVc, 13% TIV) and 9 to <18-year-olds (21% TIVc, 26% TIV).
There were no cases of severe fever (40 8C). No vaccine-related serious AEs were noted. New onset of
chronic disease was reported in 1% of subjects.
Conclusion: TIVc and TIV had acceptable tolerability and similar safety proﬁles in at-risk children
(NCT01998477).
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Inﬂuenza vaccines have traditionally been produced in
embryonated chicken eggs.1 However, using the egg-based* Corresponding author. Tel.: +1-647-823-2738; fax: +1-514-420-7441.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).manufacturing platform has challenges, such as low production
yields, risk of microbial contamination, and poor growth of some
human inﬂuenza viruses in eggs, which can cause potential delays,
long lead times, and a limited manufacturing capacity to meet the
global need, especially in the event of a pandemic.1,2 Cell culture-
based technology offers an alternative manufacturing method that
can be used as a supplement during times of inﬂuenza vaccine
demand .2 To date, three mammalian cell lines have been used forciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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kidney (MDCK) cell line, a monkey kidney cell line (Vero), and an
adenovirus-transformed human retinal cell line (PER.C6).1
Optaﬂu (Novartis Vaccines and Diagnostics GmbH, Marburg,
Germany) is a seasonal, trivalent, cell culture-derived, inactivated
subunit vaccine (TIVc) prepared by propagation of inﬂuenza virus
in MDCK continuous cell lines.3 This vaccine has been approved in
Europe since 2007 for use in individuals aged 18 years. It was
subsequently licensed in the USA in 2012 for use in adults, under
the trade name Flucelvax.4,5 Clinical trials have shown the efﬁcacy,
immunogenicity, and safety proﬁle of the TIVc vaccine to be similar
to that of egg-derived inﬂuenza vaccines in adults and the
elderly.6–10 A review of data from the Vaccine Adverse Event
Reporting System for people aged <18 years vaccinated with a
seasonal, trivalent, cell culture-derived, inactivated subunit
vaccine did not identify any adverse event (AE) patterns of
concern or any new events compared with those reported in
clinical trials. The most common category reported was ‘general
disorders and administration conditions’ (n = 152, 49%), related
mostly to injection site and systemic reactions, and there were 19
(6%) serious AEs.11 TIVc is not yet approved for use in children.
In a recent report, the US Centers for Disease Control and
Prevention estimated that inﬂuenza vaccination prevented ap-
proximately 7.2 million illnesses, 3.1 million medically attended
illnesses, and 90 000 hospitalizations associated with inﬂuenza in
the 2013–2014 inﬂuenza season in the USA alone.12 Seasonal
inﬂuenza vaccination is recommended by the World Health
Organization (WHO) particularly for those at higher risk of serious
inﬂuenza-related complications.13 These include pregnant wom-
en, children aged 6 months to 5 years, the elderly (65 years of
age), individuals with chronic medical conditions, and healthcare
workers. The burden of inﬂuenza is highest in children, and studies
have shown that the impact is higher in children with comorbid-
ities.14,15 In this descriptive, non-comparative study, the safety and
tolerability proﬁle of the cell culture-derived inﬂuenza vaccine
(TIVc) and a licensed egg-based trivalent inﬂuenza vaccine (TIV)
was assessed in children and adolescents aged 3 to <18 years with
underlying medical conditions, who are at high risk of inﬂuenza-
related complications.
2. Methods
This phase III, randomized, observer-blind, non-comparative
multicentre descriptive study was conducted in Spain (12 centres)
and Italy (four centres) from October 2013 to July 2014. The study
was conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice and was approved by the ethics review
committees concerned. Written informed consent was obtained
from the parents or guardians of all participants, and where
applicable, informed assent was also sought from the subjects. This
study is registered at ClinicalTrials.gov (NCT01998477).
Based on previous inﬂuenza vaccination status (number of
doses and type of inﬂuenza vaccines received), children were
classiﬁed into two subpopulations: subjects aged <9 years who
had not received at least two doses of seasonal inﬂuenza vaccine
since the year 2010 were classiﬁed as ‘not previously vaccinated’
(vaccine-naive); all subjects >9 years by default and subjects <9
years who had received at least two doses of seasonal inﬂuenza
vaccine since the year 2010 were considered as ‘previously
vaccinated’ (vaccine-non-naive). Randomization was stratiﬁed
by age (3 to <9 years; 9 to <18 years) and by previous inﬂuenza
vaccination status (previously vaccinated; not previously vacci-
nated). The list of randomization assignments was produced by a
validated web-based randomization (WBR) system used by the
Biostatistics and Clinical Data Management (BCDM) department of
Novartis Vaccines and Diagnostics. Enrolled subjects within eachstratum were randomized in a blinded manner 2:1 to receive either
TIVc or TIV by the investigator. In each vaccine group, subjects
were further stratiﬁed by age (3 to <9 years cohort and 9 to <18
years cohort). Subjects in the 3 to <9 years cohort received either
one dose (if previously vaccinated) on day 1 or two doses of the
vaccine (if not previously vaccinated) administered 4 weeks apart
(day 1 and day 29); all subjects in the 9 to <18 years of age cohort
received one dose of the vaccine on day 1. There was no
stratiﬁcation by comorbidity. The subjects were followed for
safety for 6 months after last vaccination.
The trial was designed as an observer-blind study. During the
study, designated unblinded nurses and physicians were respon-
sible for administering the study vaccines to the subjects and were
instructed not to reveal the identity of the study vaccines to either
the subject or the investigative site personnel involved in the
monitoring of the conduct of the trial, except in an emergency.
2.1. Subjects
Male and female children aged 3 to <18 years who were at high
risk of inﬂuenza-related complications with a conﬁrmed medical
history of any of the following diseases were eligible for
enrolment: endocrine disorders, chronic cardiovascular diseases,
chronic pulmonary diseases, chronic renal or hepatic diseases,
neurological and neurodevelopmental conditions, blood disorders,
metabolic disorders, weakened immune system due to disease
(such as HIV, AIDS, or cancer) or medication (such as corticoste-
roids), morbid obesity (deﬁned by local standards), or recipient of
long-term aspirin therapy. Subjects were excluded if they had a
history of Guillain–Barre´ syndrome or a history of anaphylaxis;
hypersensitivity or previous adverse reactions to any vaccine
components; were hospitalized or terminally ill (life-expectancy
<12 months); had received any vaccination within 2 weeks
(inactivated vaccines) or 4 weeks (live vaccines) preceding the
trial; had received seasonal inﬂuenza vaccination within 6 months
prior to study start or any other investigational agent 1 month
prior to enrolment, or planned to receive such an agent before
completion of the safety follow-up phase; had a body temperature
38 8C within 3 days of intended vaccination. Females who were
pregnant or of child-bearing potential and who were unwilling to
use acceptable birth control measures within 2 months prior to
enrolment and through the course of the study were also excluded.
2.2. Vaccines
Each 0.5-ml dose of the investigational MDCK cell culture-
derived trivalent inﬂuenza vaccine, Optaﬂu (Novartis Vaccines and
Diagnostics), contained puriﬁed viral haemagglutinin (HA) and
neuraminidase (NA) antigens, approximately 15 mg of HA for each
of the WHO reference strains recommended for the 2013–2014
inﬂuenza season for the Northern Hemisphere: A/Brisbane/10/2010
(H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012.
Each 0.5-ml dose of the egg-derived trivalent inﬂuenza vaccine,
Agrippal (Novartis Vaccines and Diagnostics, Italy), contained
approximately15 mg of HA for each strain A/California/07/2009
(H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012, as
recommended for the 2013–2014 inﬂuenza season.
The vaccines were administered by unblinded personnel in the
deltoid muscle, preferably of the non-dominant arm. To avoid any
potential bias, the unblinded personnel had no other involvement
in subject evaluation or other aspects of the study.
2.3. Safety
AEs were gathered separately after both the ﬁrst and second
vaccinations. Subjects were observed for 30 min after both the ﬁrst
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parents/guardians were provided with diary cards to record the
solicited AEs occurring within 1 week of each vaccination (i.e., days
1–7 for all subjects and additionally between days 29 and 36 for
not previously vaccinated subjects) as well as the unsolicited AEs
occurring after vaccination between days 1 and 29 (previously
vaccinated subjects who received one dose) and days 1 and 57 (not
previously vaccinated subjects who received two doses). Age-
appropriate solicited AEs were collected. For subjects aged <6
years, the solicited local AEs were injection site erythema, injection
site ecchymosis, and injection site tenderness, and the systemic
AEs were change in eating habits, shivering, sleepiness, irritability,
vomiting, diarrhoea, and fever (body temperature 38 8C). For
subjects aged 6 years, the solicited local AEs were injection site
erythema, injection site ecchymosis, and injection site pain, and
the systemic AEs were loss of appetite, nausea, fatigue, generalized
myalgia, generalized arthralgia, headache, shivering, vomiting,
diarrhoea, and fever. In addition, other indicators of reactogenicity
were also collected, including the use of analgesic/antipyretic
medication for prophylaxis and treatment. The AEs were classiﬁed
as ‘mild’ if the event was transient with no limitation in normal
daily activity, ‘moderate’ if the event led to some limitation in
normal daily activity, or ‘severe’ if the event meant the subject was
unable to perform normal daily activities.
The new onset of chronic disease (NOCD), serious AEs (SAEs),
medically attended AEs, and AEs leading to withdrawal were
captured throughout the study period, i.e., days 1–181 for
previously vaccinated subjects and days 1–209 for not previously
vaccinated subjects. All AEs were to be monitored until resolution,
or if an AE became chronic, a cause was to be determined. For any
ongoing AEs at study conclusion, the need for follow-up was basedFigure 1. Particon the investigator’s assessment. Unsolicited AEs were judged as
probably related, possibly related, or not related to vaccination by
the investigator.
2.4. Statistical analysis
Assuming a 10% dropout rate, a total of 504 subjects were
planned to be enrolled in the study so as to have 450 evaluable
subjects (300 in the TIVc group and 150 in the TIV group). With a
sample size of 300 subjects in the TIVc group, the probability of
observing at least one AE was 95% when the rate of the event is 0.01
(1 in 100), while among 450 subjects exposed to any of the two
study vaccines, the probability would be 99%. Safety data were
evaluated descriptively and for each vaccination are expressed as
the frequencies and percentages of subjects reporting AEs. Safety
analyses are presented by overall vaccine group (3 to <18 years)
and individual age cohorts (3 to <9 years and 9 to <18 years) and
by vaccination status (previously vaccinated and not previously
vaccinated). All subjects who received at least one study
vaccination and provided post-vaccination reactogenicity data
were included in the safety set solicited AEs; all subjects who
provided post-vaccination unsolicited data were included in the
safety set unsolicited AEs. The overall safety set consisted of all
participants who provided either post-vaccination reactogenicity
data or unsolicited data.
3. Results
The ﬁrst subject was recruited on October 25, 2013 and the last
completed the study on July 31, 2014. Follow-up was approxi-
mately 6 months for each patient. The study was stopped at theipant Flow.
Table 2
Underlying medical history by system organ class (SOC) of enrolled subjects in each
vaccine group
Medical history summary TIVc
n = 282, n (%)
TIV
n = 148, n (%)
Blood and lymphatic system disorders 9 (3) 6 (4)
Cardiac disorders 7 (2) 3 (2)
Congenital, familial, and genetic
disorders
60 (21) 30 (20)
Ear and labyrinth disorders 2 (1) 1 (1)
Endocrine disorders 10 (4) 5 (3)
Eye disorders 13 (5) 7 (5)
Gastrointestinal disorders 18 (6) 14 (9)
General disorders and administration
site conditions
2 (1) 1 (1)
Hepatobiliary disorders 2 (1) 3 (2)
Immune system disorders 15 (5) 13 (9)
Infections and infestations 63 (22) 36 (24)
Investigations 5 (2) 1 (1)
Metabolism and nutrition disorders 40 (14) 15 (10)
Musculoskeletal and connective
tissue disorders
14 (5) 12 (8)
Neoplasms benign, malignant,
and unspeciﬁed
13 (5) 8 (5)
Nervous system disorders 29 (10) 11 (7)
Psychiatric disorders 21 (7) 9 (6)
Renal and urinary disorders 14 (5) 6 (4)
Reproductive system and breast
disorders
1 (<1) 0
Respiratory, thoracic, and
mediastinal disorders
138 (49) 75 (51)
Skin and subcutaneous tissue disorders 23 (8) 7 (5)
Surgical and medical procedures 21 (7) 9 (6)
Vascular disorders 1 (<1) 2 (1)
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent
inﬂuenza vaccine.
J. Diez-Domingo et al. / International Journal of Infectious Diseases 49 (2016) 171–178174end of the vaccination season before reaching the target enrolment
of 504 participants. Of the total 430 subjects enrolled in the study,
96% of subjects in the TIVc group and 97% in the TIV group
completed the study protocol (Figure 1). A total of 426 vaccinated
subjects provided safety data for at least one time point and were
included in the overall safety set. The baseline demographics of the
enrolled study population are presented in Table 1. Both vaccine
groups were balanced with respect to mean age, sex, and ethnicity.
A summary of the underlying medical conditions of the subjects
enrolled is given in Table 2; these were similar in the two vaccine
groups .
3.1. Solicited adverse events
Overall, 73% of subjects in the TIVc and TIV groups reported at
least one solicited AE. Rates of any solicited AEs were lower after
the second vaccine dose than following the ﬁrst dose, and this
difference was more pronounced in the TIV group than in the TIVc
group (Table 3). The majority of AEs were mild or moderate in
severity. The most commonly reported solicited local and systemic
AEs, respectively, were injection site tenderness (44% in TIVc and
56% in TIV) and irritability (22% in TIVc and 24% in TIV) in subjects
aged <6 years, and injection site pain (57% in TIVc and 60% in TIV)
and headache (21% TIVc and 22% in TIV) in subjects 6 years of age.
Mild to moderate fever (38 8C to 40 8C) was reported by 7% of
subjects in the TIVc group and 4% in the TIV group. No cases of
severe fever (40.0 8C) were reported in the study. A similar
percentage of subjects in the two vaccine groups reported
analgesic and antipyretic use for treatment (12% in TIVc and 9%
in TIV) and prophylaxis (8% in TIVc and 7% in TIV).
In the 3 to <6 years previously vaccinated group, injection site
tenderness was reported in 36% (n = 10/28) of subjects in the TIVc
group and 58% (n = 11/19) in the TIV group (Table 4). One case each
of severe erythema (>50 mm), severe induration (>50 mm),
severe chills, and severe irritability were reported in the TIV
group. Fever was reported by four subjects in the TIVc group and by
three subjects in the TIV group (Table 4). In the 3 to <6 years not
previously vaccinated TIVc group, one subject reported severe
chills and 18% of subjects reported fever (n = 9/50; eight subjects
after the ﬁrst vaccination and two subjects after the second
vaccination). No fever was reported in the TIV group (Table 4).
In the 6 to <9 years previously vaccinated group, solicited local
and systemic AEs were reported by 62% and 35% of subjects in theTable 1
Study population demographics
3 to <9 years 9 to <18 years
TIVc
n = 140
TIV
n = 74
TIVc
n = 142
TIV
n = 74
Mean age,
years  SD
5.3  1.8 5.7  1.7 12.1  2.3 12.3  2.5
Not previously
vaccinated, n
86 39 - -
Previously
vaccinated, n
54 35 142 74
Male, % 58 58 56 57
Race, %
White 86 85 91 92
Black/African
American
1 1 <1 4
Asian 0 3 1 0
Other 12 11 7 4
Mean weight,
kg  SD
22.4  7.5 24.2  8.6 48.7  16.6 47.5  13.8
Mean height,
cm  SD
114.2  13.7 115.7  13.2 152.0  14.3 151.8  14.8
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent
inﬂuenza vaccine; SD, standard deviation.TIVc group and by 50% and 31% of subjects in the TIV group,
respectively (Table 5). There were no reports of severe AEs in the
TIVc group; one case each of severe erythema (>100 mm) and
severe induration (>100 mm) were reported in the TIV group.
Fever was reported by one subject (4%) in the TIVc group (Table 5).
In the 6 to <9 years not previously vaccinated group, injection site
pain was reported by 73% (n = 24/33) of subjects in the TIVc group
and 52% (n = 12/23) in the TIV group (Table 5). One case each of
severe pain and severe myalgia were reported in the TIVc group
(after second vaccination). Fever was reported by one subject in the
TIVc group (after ﬁrst vaccination); there were no reports of fever
in the TIV group.
In the 9 to <18 years group, solicited local and systemic AEs
were reported by 59% and 42%, respectively, of subjects in the TIVc
group and by 68% and 43%, respectively, of subjects in the TIV
group. Severe pain was reported by one subject in each vaccine
group. Two subjects in the TIVc group had severe erythema
(>100 mm); four subjects in the TIV group had severe induration
(>100 mm). Severe systemic AEs were reported by 1% of subjects
in the TIVc group and by 1–3% of subjects in the TIV group. Fever
was reported by 3% (n = 4/137) of subjects in the TIVc group and 4%
(n = 3/72) in the TIV group (Table 6).
3.2. Unsolicited adverse events
During the entire study period (day 1 to day 181/day 209), a
similar percentage of subjects reported unsolicited AEs in the TIVc
and the TIV groups (Table 7). A higher percentage of subjects in the
3 to <9 years group, both in the previously vaccinated (85% TIVc
and 83% TIV) and not previously vaccinated (91% TIVc and 82% TIV)
groups, reported unsolicited AEs than in the 9 to <18 years group
(65% in TIVc and 68% in TIV). Across age groups, between 5% and 7%
of subjects in the TIVc group and 5% and 13% in the TIV group
Table 3
Subjects aged 3 to <18 years with solicited AEs from day 1 to day 7 after each/any vaccination, by vaccine group (safety set solicited AEs)
TIVc, n (%) TIV, n (%)
Dose 1
n = 277
Dose 2a
n = 83
Any
n = 277
Dose 1
n = 145
Dose 2a
n = 40
Any
n = 146
Any solicited AE 193 (70) 49 (59) 202 (73) 105 (72) 21 (53) 107 (73)
Local 149 (54) 41 (49) 163 (59) 89 (61) 18 (45) 91 (62)
Systemic 117 (42) 29 (35) 128 (46) 55 (38) 8 (20) 58 (40)
AE, adverse event; TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent inﬂuenza vaccine.
a Second vaccine dose was given only to vaccine-naive children (not previously vaccinated) in the 3 to <9 years cohort.
Table 4
Solicited adverse events in subjects aged 3 to <6 yearsa
Event Previously vaccinated, n (%) Not previously vaccinated, n (%)
TIVc n = 28 TIV n = 19 TIVc n = 50 TIV n = 15
Local adverse events
Tenderness Mild 7 (25) 9 (47) 17 (34) 4 (27)
Moderate 3 (11) 2 (11) 7 (14) 4 (27)
Severe 0 0 0 0
Erythema Mild 5 (19) 1 (6) 1 (2) 3 (20)
Moderate 2 (7) 2 (11) 3 (6) 1 (7)
Severe 0 1 (6) 0 0
Induration Mild 2 (7) 0 3 (6) 3 (20)
Moderate 0 1 (5) 5 (10) 1 (7)
Severe 0 1 (5) 0 0
Ecchymosis Mild 1 (4) 1 (5) 4 (8) 2 (13)
Moderate 1 (4) 1 (5) 1 (2) 2 (13)
Severe 0 0 0 0
Systemic adverse events
Change in eating habits Mild 2 (7) 1 (5) 9 (18) 4 (27)
Moderate 3 (11) 2 (11) 3 (6) 0
Severe 0 0 0 0
Chills Mild 1 (4) 1 (5) 6 (12) 0
Moderate 1 (4) 0 0 0
Severe 0 1 (5) 1 (2) 0
Diarrhoea Mild 3 (11) 1 (5) 2 (4) 1 (7)
Moderate 0 0 0 1 (7)
Severe 0 0 0 0
Irritability Mild 4 (14) 3 (16) 9 (18) 2 (13)
Moderate 2 (7) 1 (5) 2 (4) 1 (7)
Severe 0 1 (5) 0 0
Sleepiness Mild 4 (14) 3 (16) 7 (14) 2 (13)
Moderate 0 0 3 (6) 0
Severe 0 0 0 0
Vomiting Mild 3 (11) 1 (5) 4 (8) 1 (7)
Moderate 0 0 1 (2) 0
Severe 0 0 0 0
Fever Mild 3 (11) 1 (5) 7 (14) 0
Moderate 0 2 (11) 2 (4) 0
Severe 1 (4) 0 0 0
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent inﬂuenza vaccine.
a Grading for erythema, ecchymosis, and induration: mild (1–9 mm), moderate (10–50 mm), severe (>50 mm); mild fever (38 8C to <39 8C), moderate fever (39 8C to
<40 8C), severe fever (40 8C).
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to study vaccination. The majority of the possibly related AEs were
solicited local and systemic AEs that persisted beyond day 7, in
both vaccine groups.
The most frequently reported unsolicited AEs in both vaccine
groups, as per the Medical Dictionary for Regulatory Activities
(MedDRA) system organ classes (SOC) were classiﬁed as ‘infections
and infestations’ (51% in TIVc and 49% in TIV), ‘respiratory,
thoracic, and mediastinal disorder’ (26% in TIVc and 23% in TIV),
and ‘general disorders and administrative conditions’ (12% in TIVc
and 16% in TIV).
3.3. Serious adverse events
A total of 22 SAEs were reported by 16 subjects; 17 SAEs in
12 subjects (4%) in the TIVc group and ﬁve SAEs in four subjects(3%) in the TIV group. No SAE was considered to be vaccine-related
(Table 7). The SAEs were reported by a similar percentage of
subjects in the TIVc (4%) and the TIV (6%) groups in the 3 to <9
years previously vaccinated group. Among the 3 to <9 years not
previously vaccinated group, 5% of subjects in the TIVc group
reported SAEs, while there were no reports of SAEs in the TIV
group. In the 9 to <18 years age cohort, 4% of subjects in the TIVc
group and 3% in the TIV group reported SAEs.
3.4. New onset of chronic disease
NOCD was reported in four subjects (n = 3 in TIVc and n = 1 in
TIV). The following NOCDs by MedDRA preferred term were
reported in the study: refraction disorder, drug resistance and
hypertensive crisis, toxic encephalopathy, and vomiting and
decreased appetite.
Table 5
Solicited adverse events in subjects aged 6 to <9 yearsa
Event Previously
vaccinated, n (%)
Not previously
vaccinated, n (%)
TIVc
n = 26
TIV
n = 16
TIVc
n = 32–35
TIV
n = 22–24
Local adverse events
Pain Mild 13 (50) 5 (31) 16 (48) 12 (52)
Moderate 2 (8) 3 (19) 7 (21) 0
Severe 0 0 1 (3) 0
Erythema Mild 1 (4) 2 (13) 5 (15) 2 (8)
Moderate 0 1 (6) 2 (6) 3 (12)
Severe 0 1 (6) 0 0
Induration Mild 1 (4) 0 4 (12) 1 (4)
Moderate 0 2 (13) 2 (6) 3 (13)
Severe 0 1 (6) 0 0
Ecchymosis Mild 2 (8) 0 5 (15) 4 (17)
Moderate 0 0 0 1 (4)
Severe 0 0 0 0
Systemic adverse events
Chills Mild 3 (12) 0 5 (15) 0
Moderate 0 1 (6) 0 0
Severe 0 0 0 0
Diarrhoea Mild 1 (4) 0 4 (12) 1 (4)
Moderate 0 0 0 0
Severe 0 0 0 0
Vomiting Mild 0 0 4 (12) 0
Moderate 0 1 (6) 0 0
Severe 0 0 0 0
Arthralgia Mild 2 (8) 1 (6) 4 (12) 1 (5)
Moderate 0 0 0 0
Severe 0 0 0 0
Fatigue Mild 2 (8) 2 (13) 3 (9) 0
Moderate 0 0 2 (6) 0
Severe 0 0 0 0
Headache Mild 0 2 (13) 10 (30) 1 (5)
Moderate 1 (4) 1 (6) 1 (3) 1 (5)
Severe 0 0 0 0
Loss of appetite Mild 2 (8) 1 (6) 7 (21) 1 (4)
Moderate 0 1 (6) 3 (9) 2 (9)
Severe 0 0 0 0
Myalgia Mild 4 (15) 1 (6) 5 (15) 1 (5)
Moderate 0 1 (6) 1 (3) 0
Severe 0 0 1 (3) 0
Nausea Mild 1 (4) 1 (6) 2 (6) 0
Moderate 0 1 (6) 1 (3) 0
Severe 0 0 0 0
Fever Mild 1 (4) 0 1 (3) 0
Moderate 0 0 0 0
Severe 0 0 0 0
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent
inﬂuenza vaccine.
a Grading for erythema, ecchymosis, and induration: mild (1–9 mm), moderate
(10–50 mm), severe (>50 mm); mild fever (38 8C to <39 8C), moderate fever
(39 8C to <40 8C), severe fever (40 8C).
Table 6
Solicited adverse events in subjects 9 to <18 years of agea
Event TIVc n = 138
n (%)
TIV n = 72
n (%)
Local adverse events
Pain Mild 57 (41) 33 (46)
Moderate 15 (11) 13 (18)
Severe 1 (1) 1 (1)
Erythema Mild 0 0
Moderate 3 (2) 2 (3)
Severe 2 (2) 0
Induration Mild 1 (1) 1 (2)
Moderate 4 (3) 2 (3)
Severe 1 (1) 4 (7)
Ecchymosis Mild 0 0
Moderate 0 0
Severe 0 0
Systemic adverse events
Chills Mild 14 (10) 4 (6)
Moderate 4 (3) 2 (3)
Severe 1 (1) 0
Diarrhoea Mild 7 (5) 3 (4)
Moderate 4 (3) 1 (1)
Severe 0 0
Vomiting Mild 6 (4) 1 (1)
Moderate 0 2 (3)
Severe 2 (1) 0
Arthralgia Mild 14 (10) 6 (8)
Moderate 3 (2) 1 (1)
Severe 1 (1) 0
Fatigue Mild 11 (8) 9 (13)
Moderate 10 (7) 4 (6)
Severe 2 (1) 1 (1)
Headache Mild 18 (13) 12 (17)
Moderate 10 (7) 6 (8)
Severe 1 (1) 1 (1)
Loss of appetite Mild 14 (10) 9 (13)
Moderate 5 (4) 3 (4)
Severe 1 (1) 0
Myalgia Mild 24 (17) 9 (13)
Moderate 4 (3) 2 (3)
Severe 1 (1) 0
Nausea Mild 10 (7) 6 (8)
Moderate 5 (4) 2 (3)
Severe 2 (1) 2 (3)
Fever Mild 4 (3) 3 (4)
Moderate 0 0
Severe 0 0
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent
inﬂuenza vaccine.
a Grading for erythema, ecchymosis, and induration: mild (1–9 mm), moderate
(10–50 mm), severe (>50 mm); mild fever (38 8C to <39 8C), moderate fever
(39 8C to <40 8C), severe fever (40 8C).
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A similar percentage of subjects reported medically attended
AEs in the two vaccine groups (Table 7). When analyzed by age
cohort, the frequency of medically attended AEs was 84% in the
TIVc group and 72% in the TIV group in the 3 to <9 years not
previously vaccinated group. In the 3 to <9 years previously
vaccinated group, the reported rates were 70% in TIVc and 69% in
TIV. Overall, the rate of medically attended AEs in the 3 to <9-
year-old subjects was higher in those who had received two doses
than in those who had received one dose of TIVc, while rates were
similar in the TIV groups. In the 9 to <18 years group, the rates of
medically attended AEs were lower (56% in TIVc and 59% in TIV)
than those reported in the younger age group in either vaccine
group. The most frequently reported medically attended MedDRA
AEs were ‘infections and infestations’, followed by ‘respiratory,
thoracic, and mediastinal disorders’ and ‘gastrointestinal dis-
orders’.3.6. AEs leading to withdrawal and deaths
There were no AEs reported that led to withdrawal of the
subject in either vaccine group. No deaths were reported during
the study period.
4. Discussion
TIVc is at present the only cell culture-derived seasonal
inﬂuenza vaccine that is licensed for use in adults and is especially
indicated for individuals at risk of inﬂuenza infection.4 This
descriptive, non-comparative study is the ﬁrst to evaluate the
safety of TIVc in 3 to <18-year-old children and adolescents who
are at risk of inﬂuenza-related complications. The two vaccine
groups were balanced with respect to mean age, sex, and ethnicity,
and the comorbidities recorded were similar in the two groups.
These results show TIVc has an acceptable tolerability proﬁle in
this age group, with most solicited AEs resolving within 7 days of
vaccination. The reported rates of AEs were similar in the TIVc and
TIV groups.
Table 7
Subjects aged 3 to <18 years reporting unsolicited adverse events after any
vaccination, by vaccine group
Vaccine groups TIVc
N = 278
n (%)
TIV
N = 148
n (%)
Any AE 213 (77) 111 (75)
Any possibly related AE 17 (6) 12 (8)
Any SAE 12 (4) 4 (3)
Any possibly related SAE 0 0
Any NOCD 3 (1) 1(1)
Medically attended AEs 187 (67) 94 (64)
AEs leading to withdrawal 0 0
Death 0 0
TIVc, cell culture-derived trivalent inﬂuenza vaccine; TIV, egg-derived trivalent
inﬂuenza vaccine; AE, adverse event; SAE, serious adverse event; NOCD, new onset
of chronic disease.
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vaccination in this study are similar to those reported in healthy
children.16–18 As in healthy subjects, the most common solicited
local AE with TIVc in at-risk children was tenderness/pain at the
injection site; the most common systemic AE was irritability in
younger children (<6 years) and headache and myalgia in older
children. Some studies in adults have reported a higher frequency
of injection site pain associated with TIVc compared to TIV.10
However, this was not observed in the present paediatric study.
Furthermore, the rates of AEs observed in this study are higher
than those reported from a phase III study of the same cell culture-
derived vaccine in healthy children and adolescents.17 This may be
because children who are at risk of inﬂuenza complications, such
as those enrolled in this study, are likely to have comorbidities that
could increase their susceptibility to reactions.
The ﬁndings from clinical trials involving >5000 healthy
children and adolescents and from a large pooled safety analysis
from two studies in 4 to <17-year-old healthy children and
adolescents have demonstrated that the safety proﬁle of TIVc is
similar to that of licensed egg-derived inﬂuenza vaccines.16–18 The
results of the present study are consistent with these ﬁndings, as
they demonstrated that the relative risk estimates for experiencing
solicited AEs with TIVc were similar to those with egg-derived
vaccine.18 Cell culture-based manufacturing of inﬂuenza vaccines
provides a valuable alternative to egg-based systems and can yield
a virus that, for some strains, is a closer match to the circulating
strains than those produced in eggs;1,2 therefore it is important to
assess the safety of cell culture-derived vaccines in all populations.
To date, safety assessments have shown that vaccines produced
using MDCK cell lines are non-oncogenic and non-tumorigen-
ic,19,20 and post-marketing surveillance has shown that the
inﬂuenza A/H1N1 monovalent adjuvanted cell culture-derived
inﬂuenza vaccine is not associated with any AEs of special
interest.21
This study had some limitations. The target sample size was not
achieved, primarily because the study started almost a month after
inﬂuenza vaccinations had begun for the season. As high-risk
subjects receive inﬂuenza vaccination as a priority, the delayed
start affected enrolment. The sample size was also not sufﬁcient to
capture rare AEs and no formal statistical comparisons were
performed between the two vaccine groups. Nevertheless, these
results do provide a substantial insight into the safety of cell
culture-derived inﬂuenza vaccine in at-risk children.
In conclusion, TIVc had an acceptable tolerability proﬁle in
children and adolescents with comorbidities in this study, with no
potential safety signals identiﬁed with vaccines during the 6-
month follow-up. The pattern of AEs observed after TIVc
vaccination was similar to that observed with the licensed egg-based TIV in this population. These study results also expand the
safety database of TIVc vaccine in the paediatric population.
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